Cantargia AB (publ) (CANTA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Good afternoon, everyone, and thank you for joining us. I'm Hilde Steininger, CEO of Kantarga. Today, I will present our Q1 2026 update and progress across all our IL-1 RAP1 platform, including how we are adapting our oncology strategy to an evolving treatment landscape. Next slide, please. Before we begin, I'd like to include forward-looking statements. These reflects our current expectation and involve risk and uncertainties that could cause actual outcomes to differ materially. I'd ask everyone to read this statement carefully and keep it in mind throughout the presentation. Next slide, please. I'm joined today by Patrick Remblad, our Chief Financial Officer. Together, we'll take you through the developments in the last quarter. We'll start with the strategic perspectives, then move through the portfolio, clinical updates and key financials. Next slide, please. So today I wanted to outline how we are refining our development focus across the company's core value drivers. In PDAC, recent clinical advances have increased focus to this disease area, and the treatment landscape is evolving quickly, with RAS inhibitors poised to become an important part of future care. Against that backdrop, we see a clear opportunity for Nanolumab in combination settings, and we are refining the design and timing of our planned phase 2b3 study to better position the program in this emerging landscape. In hematology, we see early and encouraging signals from the MD Anderson study in MDS, supported by a strong scientific rationale for IL-1 rep in hematologic malignancies. Beyond this, we are maintaining a long-term pipeline perspective, including our next generation bispecific work in inflammation building on the biology behind Can10. Finally, Wolfram Demcke will transition f...